title: A multicenter randomized controlled trial of a liquid loperamide product versus placebo in the treatment of acute diarrhea in children.
abstract: This randomized, double-blind, placebo-controlled trial of 48 hours' duration conducted in 13 primary care ambulatory practices in the United States and Mexico was used to compare the efficacy and safety of loperamide with placebo for the treatment of acute diarrhea in children aged 2 through 11 years. Two hundred fifty-eight children with acute nonspecific diarrhea were enrolled. Children were randomly assigned to treatment with loperamide HCl 0.5 mg/5 mL (n = 130) or placebo (n = 128). The first dose of loperamide consisted of either 1.0 mg (children 2 through 5 years of age) or 2.0 mg (children 6 through 11 years of age) of study medication under the observation of study personnel. This was followed by 1 mg after each unformed stool, with a total daily dose of up to 3.0 mg in the children 2-5 years of age, 4.0 mg in the children 6-8 years of age, and 6.0 mg in the children 9-11 years of age. The primary outcome measures were time to last unformed stool, time to first unformed stool, number of unformed stools during six consecutive 8-hour periods, and overall rating of efficacy/acceptability. Secondary outcomes included abdominal pain/cramping, vomiting, and fever. Children who received loperamide had significantly shorter time to last unformed stool (p = 0.0017) and fewer numbers of unformed stools (p = 0.0237) than children who received placebo. The end-of-study overall efficacy/acceptability rating of loperamide was significantly better than for placebo (p = 0.0107). All other clinically important outcome measures related to diarrhea relief favored loperamide. There was no significant difference in the incidence of drug-related adverse events between treatment groups, although total adverse events were reported more frequently (p = 0.048) by the loperamide group (15%) compared with the placebo group (7%). In conclusion, this controlled study provides data demonstrating that at recommend doses, loperamide is well tolerated and significantly shortens the duration and severity of symptoms of acute nonspecific diarrhea in children 2 through 11 years of age.
authors.affiliation: Medical Department, McNeil Consumer Healthcare, Fort Washington, PA 19034, USA.
authors.forename: M A
authors.initials: MA
authors.lastname: Kaplan
authors.forename: M J
authors.initials: MJ
authors.lastname: Prior
authors.forename: K I
authors.initials: KI
authors.lastname: McKonly
authors.forename: H L
authors.initials: HL
authors.lastname: DuPont
authors.forename: A R
authors.initials: AR
authors.lastname: Temple
authors.forename: E B
authors.initials: EB
authors.lastname: Nelson
mesh_terms: D000208:Acute Disease; D002648:Child; D002675:Child, Preschool; D003968:Diarrhea, Infantile / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007223:Infant; D008139:Loperamide / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D010919:Placebos
chemical_list: D010919:Placebos; D008139:Loperamide